RENFLEXIS® is indicated to treat:
- Crohn’s Disease
- Ulcerative Colitis
- Pediatric Ulcerative Colitis
- Pediatric Crohn’s Disease
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
RENFLEXIS, Infliximab-abda, a biosimilar to Remicade, is a drug used in the treatment of Inflammatory Bowel Disease, as well as other autoimmune diseases. It is a weight-based medication following a recommended induction dose of 5mg/kg and maintenance dose of 10mg/kg (per Prescribing Doctor’s recommendation). The medication is infused intravenously in intervals at week 0, 2, 6 and then every 8 weeks for maintenance.
For more information, click here to visit the manufacturer’s website: https://www.renflexis.com
Ready to Start with Specialty Infusion?
It’s easy to transition your treatment to Specialty Infusion. Here’s how it works:
Ask your doctor to send a prescription, clinical notes, demographics and your insurance card.
One of our Care Coordinators will contact you to confirm receipt of your referral and provide guidance on the next steps.
Your Care Coordinator will contact your insurance company to conduct an investigation of benefits and initiate authorization to ensure coverage of your treatment.
Our team works diligently to expedite the authorization process. Once approval is obtained, your Care Coordinator will contact you to schedule an appointment.